Response
Dr Parsons' comment raises the interesting issue of whether we should be treating our patients to optimize their blood lipid profiles or to reduce their risk for future coronary events. These 2 goals may not always be congruous. Niacin favorably modifies all of the lipoprotein end points, as Dr Parsons points out, but it did not reduce the primary end point in the only controlled clinical trial in which it was tested. 1 Statins do not increase HDL cholesterol as much as niacin can and have no beneficial effect on lipoprotein(a) [Lp(a)]. In each of the 5 major trials in which they have been tested, however, statins reduced major coronary events, with relative risk reductions from 24% to 37%.
This dilemma is not only about niacin. In postmenopausal women with coronary disease, hormone replacement therapy reduces LDL cholesterol, reduces Lp(a), and raises HDL cholesterol, but it does not reduce events. 2 Gemfibrozil significantly reduced cardiovascular events in one trial involving men with coronary disease, low HDL cholesterol, and no elevation of LDL cholesterol; 3 however, meta-analysis of older fibrate trials has raised the suspicion that drugs from this class may increase noncardiovascular mortality. 4 It may turn out that the safest and most effective way to reduce cardiovascular events in patients with low HDL cholesterol, high Lp(a), or even diabetes is not to treat the biochemical abnormality but rather to lower LDL cholesterol.
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